
    
      Seventy-eight patients with upper extremity spasticity after cerebrovascular accident will be
      recruited and randomly assigned to one of 5 groups. The groups are as followings.

      Gp 1: placebo group (Normal saline 1.2 ml) Gp 2: Clostridium Botulinum Toxin Type A (Nabota,
      DWP 450) 15 U Gp 3: Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 30 U Gp 4:
      Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 50 U Gp 5: Clostridium Botulinum Toxin
      Type A (Nabota, DWP 450) 70 U

      According to the group, the injection will be performed to the finger flexor musles (flexor
      digitorum superficialis and profundus). Outcome measurement will be MAS (Modified ashworth
      scale), FMA, Wolf Motor Assessment, Cross sectional area measured by Ultrasonography.

      Patient evaluation will be conducted 2 weeks, 1 months, 2 months, and 3 months after the
      injection.
    
  